

=&gt; d his

(FILE 'HOME' ENTERED AT 16:34:02 ON 12 DEC 2011)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS' ENTERED AT 16:34:14 ON 12 DEC 2011

L2 2739 S HU? (L) (CYTOMEGALOVIRUS OR CMV) (L) ENHANCER  
 L3 1965 S MOUSE (L) BETA (L) ACTIN (L) PROMOTER  
 L4 169 S L2 (L) L3  
 L5 62 DUP REM L4 (107 DUPLICATES REMOVED)  
 L6 38 S L5 AND PY<=2004  
 L7 38 FOCUS L6 1-  
 L8 0 S L7 AND (MOUSE BETA?)  
 L9 2 S L7 AND (MOUSE (2W) BETA?)  
 L10 9 S MOUSE B-ACTIN PROMOTER  
 L11 0 S L10 AND L2  
 L12 4 DUP REM L10 (5 DUPLICATES REMOVED)

=&gt; d ti so au ab pi l12 1-4

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2011 ACS on STN  
 TI Hybrid mouse .beta.-actin promoter with cytomegalovirus  
 enhancer/woodchuck hepatitis virus posttranscriptional regulatory element  
 and uses  
 SO PCT Int. Appl., 48 pp.  
 CODEN: PIXXD2  
 IN Tsunoda, Hiroyuki; Habu, Kiyoshi  
 AB Hybrid promoters prepared by combining various gene promoters and enhancers,  
 and use in production of desired proteins, omnipotent cells, or transgenic  
 animals, are disclosed. It was found that a hybrid promoter comprising a  
 combination of CMV enhancer with a mammalian  $\beta$ -actin promoter or a  
 combination of the Woodchuck Hepatitis Virus posttranscriptional  
 regulatory element (WPRE) with a mammalian  $\beta$ -actin promoter, is  
 superior in activity to the existing promoters. It was also found that  
 the activity of this  $\beta$ -actin promoter is enhanced by the simultaneous  
 expression of an oncogene product Ras which is a transactivator. In this  
 study the authors have enhanced the efficacy of DNA vaccines by adopting  
 strategies that increase gene expression. The authors generated  
 influenza-hemagglutinin (HA)-encoding DNA vaccines that contain the hybrid  
 CMV enhancer/chicken  $\beta$ -actin (CAG) promoter and/or the  
 mRNA-stabilizing post-transcriptional regulatory element from the  
 woodchuck hepatitis virus (WPRE). DNA vaccines consisting of both CAG and  
 WPRE elements (pCAG-HA-WPRE) induced the highest level of protective  
 immunity, such that immunization with 10-fold lower DNA doses prevented  
 death in 100% of the mice upon lethal viral challenge, whereas all mice  
 immunized with the conventional pCMV-HA vaccine succumbed to influenza  
 infection.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2005054467	A1	20050616	WO 2004-JP18006	20041203
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

STN Seach HistoryPrint selected from Online session

	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			
	EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,			
	RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,			
	MR, NE, SN, TD, TG			
AU 2004295590	A1	20050616	AU 2004-295590	20041203
AU 2004295590	B2	20100429		
CA 2548185	A1	20050616	CA 2004-2548185	20041203
EP 1707629	A1	20061004	EP 2004-819918	20041203
EP 1707629	B1	20110608		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
	IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1914320	A	20070214	CN 2004-80041348	20041203
SG 164436	A1	20100929	SG 2010-5748	20041203
EP 2270152	A1	20110105	EP 2010-10437	20041203
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			
	IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,			
	HR, LV, MK, YU			
AT 512232	T	20110615	AT 2004-819918	20041203
KR 2006123413	A	20061201	KR 2006-7013218	20060630
IN 2006DN03783	A	20070713	IN 2006-DN3783	20060630
IN 235423	A1	20090731		
US 20080250514	A1	20081009	US 2007-581183	20070518
IN 2009DN02296	A	20090612	IN 2009-DN2296	20090408